1. Autonomix Medical's abstract accepted by ASCO for pancreas cancer pain study. 2. Presentation scheduled for January 9, 2026, during ASCO Gastrointestinal Symposium. 3. Technology aims for nerve-targeted treatment using a microchip sensing array. 4. Research focuses on pain relief in pancreatic adenocarcinoma, lacking effective solutions. 5. Innovative platform may expand to multiple indications beyond current focus.
FAQ
Why Bullish?
The acceptance for presentation at ASCO highlights Autonomix's innovative research, potentially improving investor confidence, similar to past ASCO presentations enhancing related stocks historically. This could lead to increased interest and investment in AMIX as it showcases credible advancements in cancer pain management.
How important is it?
The announcement strengthens Autonomix’s position in a critical cancer treatment niche, likely enhancing its visibility and market appeal. The potential for technological advancements within a high-stakes medical area further elevates its relevance to investors and stakeholders.
Why Short Term?
The upcoming ASCO symposium in January could prompt immediate market reactions, similar to past instances where ASCO presentations significantly impacted associated stocks in the short term, given the urgency in cancer treatment innovations.
Autonomix Medical, Inc. Announces Significant Presentation at 2026 ASCO Gastrointestinal Cancers Symposium
THE WOODLANDS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) has announced that its abstract has been accepted for poster presentation at the highly anticipated 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, scheduled for January 8-10, 2026, in San Francisco, California.
Details of the Poster Presentation
The poster presentation details are as follows:
- Title: Pain mitigation in pancreatic adenocarcinoma: A long-term analysis of denervation via transvascular RF energy-based ablation
- Abstract Number: 693
- Presenter: Robert S. Schwartz, MD, Chief Medical Officer of Autonomix Medical, Inc.
- Session Title: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
- Date and Time: January 9, 2026, from 11:30 AM to 1:00 PM and 5:00 PM to 6:00 PM PST
Understanding ASCO and Its Importance
The American Society of Clinical Oncology, Inc. (ASCO), founded in 1964, is dedicated to the mission of conquering cancer through knowledge and innovation. Representing over 50,000 oncology professionals, ASCO advocates for high-quality and equitable patient care while supporting research and education initiatives to fight cancer.
Through its foundation, Conquer Cancer, ASCO is pivotal in funding groundbreaking research that spans the full continuum of cancer care.
About Autonomix Medical, Inc.
Autonomix Medical, Inc. is a pioneering medical device company focused on redefining how neurological diseases are diagnosed and treated. Central to the Company’s innovations is a first-in-class platform technology featuring a catheter-based microchip sensing array, which has the potential to detect and differentiate neural signals with advanced sensitivity.
This innovative approach aims to facilitate transvascular diagnosis and treatment of diseases impacting the peripheral nervous system across the body, particularly addressing issues like chronic pain associated with pancreatic cancer—a condition notoriously difficult to manage without effective solutions.
While initially targeting pain relief through its investigational technology, Autonomix has expressed ambition to extend its platform to various applications in cardiology, hypertension, and broader pain management across multiple disease states. Importantly, as of now, the technology has not been cleared for marketing in the United States.
Connect with Autonomix
For additional insights into Autonomix Medical, Inc. and its advancements in medical technology, visit autonomix.com. Engage with the Company through its profiles on various platforms including X, LinkedIn, Instagram, and Facebook.
Investor and Media Contact Information
For inquiries, please contact the JTC Team, LLC:
- Contact Name: Jenene Thomas
- Phone: 833-475-8247
- Email: autonomix@jtcir.com